Clinical Results and Biomarker Analyses of Axitinib and TRC105 versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (TRAXAR).
Axitinib
Carotuximab
Endoglin
Phase II
Renal cell cancer
TRAXAR
TRC105
Journal
The oncologist
ISSN: 1549-490X
Titre abrégé: Oncologist
Pays: England
ID NLM: 9607837
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
received:
01
02
2021
accepted:
05
03
2021
pubmed:
9
4
2021
medline:
13
7
2021
entrez:
8
4
2021
Statut:
ppublish
Résumé
The combination of carotuximab with axitinib did not provide a benefit over axitinib monotherapy in patients with metastatic clear cell renal cell carcinoma who had previously progressed on one or more vascular endothelial growth factor (VEGF)-targeted therapies. Exploratory evaluation of pretreatment circulating biomarkers suggested the combination might benefit patients who have low baseline VEGF levels. Endoglin is an angiogenic receptor expressed on proliferating tumor vessels and renal cell carcinoma (RCC) stem cells that is implicated as a mechanism of resistance to vascular endothelial growth factor receptor (VEGFR) inhibitors. This study evaluated an antiendoglin monoclonal antibody (carotuximab, TRC105) combined with axitinib in patients with advanced or metastatic clear cell renal cell carcinoma (mccRCC) who had progressed following one or more prior VEGF inhibitors. TRAXAR was a multicenter, international randomized 1:1 (stratified by ECOG, 0 vs. 1), phase II study of carotuximab combined with axitinib versus axitinib alone in mccRCC patients who had progressed following one or more prior VEGF inhibitors. The primary endpoint was progression-free survival (PFS) assessed by independent central review (ICR) per RECIST 1.1 RESULTS: A total of 150 patients were randomized. The combination therapy resulted in shorter median PFS by RECIST 1.1 than axitinib monotherapy (6.7 vs. 11.4 months). The combination was tolerated similarly to axitinib monotherapy, and there were no treatment related deaths. Exploratory evaluation of pretreatment circulating biomarkers suggested the combination might benefit patients who have low baseline VEGF levels. The combination of carotuximab with axitinib did not demonstrate additional efficacy over single agent axitinib in patients with mccRCC who progressed following one or more prior VEGF inhibitor treatment.
Sections du résumé
LESSONS LEARNED
The combination of carotuximab with axitinib did not provide a benefit over axitinib monotherapy in patients with metastatic clear cell renal cell carcinoma who had previously progressed on one or more vascular endothelial growth factor (VEGF)-targeted therapies. Exploratory evaluation of pretreatment circulating biomarkers suggested the combination might benefit patients who have low baseline VEGF levels.
BACKGROUND
Endoglin is an angiogenic receptor expressed on proliferating tumor vessels and renal cell carcinoma (RCC) stem cells that is implicated as a mechanism of resistance to vascular endothelial growth factor receptor (VEGFR) inhibitors. This study evaluated an antiendoglin monoclonal antibody (carotuximab, TRC105) combined with axitinib in patients with advanced or metastatic clear cell renal cell carcinoma (mccRCC) who had progressed following one or more prior VEGF inhibitors.
METHODS
TRAXAR was a multicenter, international randomized 1:1 (stratified by ECOG, 0 vs. 1), phase II study of carotuximab combined with axitinib versus axitinib alone in mccRCC patients who had progressed following one or more prior VEGF inhibitors. The primary endpoint was progression-free survival (PFS) assessed by independent central review (ICR) per RECIST 1.1 RESULTS: A total of 150 patients were randomized. The combination therapy resulted in shorter median PFS by RECIST 1.1 than axitinib monotherapy (6.7 vs. 11.4 months). The combination was tolerated similarly to axitinib monotherapy, and there were no treatment related deaths. Exploratory evaluation of pretreatment circulating biomarkers suggested the combination might benefit patients who have low baseline VEGF levels.
CONCLUSION
The combination of carotuximab with axitinib did not demonstrate additional efficacy over single agent axitinib in patients with mccRCC who progressed following one or more prior VEGF inhibitor treatment.
Identifiants
pubmed: 33829609
doi: 10.1002/onco.13777
pmc: PMC8265348
doi:
Substances chimiques
Antibodies, Monoclonal
0
Vascular Endothelial Growth Factor A
0
Axitinib
C9LVQ0YUXG
carotuximab
YB2EWE6139
Types de publication
Clinical Trial, Phase II
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
560-e1103Subventions
Organisme : NCI NIH HHS
ID : P30 CA093373
Pays : United States
Informations de copyright
© AlphaMed Press; the data published online to support this summary are the property of the authors.
Références
Gynecol Oncol. 2006 Dec;103(3):1007-11
pubmed: 16854456
Virchows Arch. 2006 Jun;448(6):768-75
pubmed: 16612622
Hum Pathol. 2006 Jul;37(7):861-6
pubmed: 16784986
BMC Cancer. 2006 May 02;6:110
pubmed: 16650286
Hum Pathol. 2016 Nov;57:98-105
pubmed: 27436827
Curr Drug Deliv. 2011 Jan;8(1):135-43
pubmed: 21034418
J Biol Chem. 2002 Nov 15;277(46):43799-808
pubmed: 12228247
Am J Clin Pathol. 2007 Apr;127(4):572-9
pubmed: 17369132
Invest New Drugs. 2014 Oct;32(5):851-9
pubmed: 24994097
Cancer Epidemiol Biomarkers Prev. 2014 Jan;23(1):117-125
pubmed: 24192008
Gynecol Oncol. 2009 Mar;112(3):469-74
pubmed: 19135712
Clin Cancer Res. 2012 Sep 1;18(17):4820-9
pubmed: 22767667
Cancer. 2014 Mar 1;120(5):692-701
pubmed: 24249435
Hum Pathol. 2005 Sep;36(9):955-61
pubmed: 16153457
Cell. 2011 Sep 16;146(6):873-87
pubmed: 21925313
Science. 1999 May 28;284(5419):1534-7
pubmed: 10348742
Neuropathology. 2005 Sep;25(3):201-6
pubmed: 16193836
Int J Gynecol Cancer. 2006 Sep-Oct;16(5):1789-93
pubmed: 17009973
Clin Cancer Res. 2017 Jul 15;23(14):3557-3565
pubmed: 28031424
Curr Pharm Des. 2006;12(10):1173-93
pubmed: 16611099
FASEB J. 2003 Jun;17(9):984-92
pubmed: 12773481
Oncologist. 2019 Feb;24(2):202-210
pubmed: 30190302
Clin Cancer Res. 2008 Apr 1;14(7):1931-7
pubmed: 18381930
Curr Oncol Rep. 2014 Feb;16(2):365
pubmed: 24445497
Cancer Res. 1999 Feb 15;59(4):856-61
pubmed: 10029075
PLoS One. 2012;7(12):e50920
pubmed: 23300529
Cancer. 2017 Dec 1;123(23):4566-4573
pubmed: 28832978
Lancet. 2011 Dec 3;378(9807):1931-9
pubmed: 22056247
Acta Otolaryngol. 2006 Jun;126(6):633-9
pubmed: 16720449